A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 2
    • Interventions: HRS-7058 + Cetuximab (Drug), HRS-7058 + SHR-1316 (Drug), HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy (Drug), HRS-7058 +… to HRS-7058 + BP102 (Drug), HRS-7058 + Cetuximab (Drug), HRS-7058 + SHR-1316 (Drug), HRS-7058 + SHR-1316 + Platinum-containing doublet…
    • Study arms: 5 to 13
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2025 to Apr 28, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Trial Details
NCT Number NCT06915142
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions
(from sponsor)		 Advanced Malignant Tumour
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov